Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



These Stocks Have Been Drawn and Quartered in 2013

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

The Dow Jones Industrial Average ended the shortened holiday week on a positive note, rising 52 points on Thursday and closing out a remarkable first quarter: the index surged almost 1,500 points for a better than 11% gain. And though its components largely basked in the glow of that run, Alcoa (NYSE: AA  ) and Caterpillar (NYSE: CAT  ) did not, being the only two stocks in the Dow that ended lower than where they started the year.

It's significant that both are seen as bellwethers for the global economy, particularly in China, which is now suffering from an economy easing back. Last year's 7.8% GDP growth marked a substantial break from a decade of breakneck expansion, and the Shanghai Composite Index contracted 1.4% in the first quarter. The U.S. Federal Reserve says that under a worst-case scenario, the Chinese economy could flatline by 2030, though the more likely outcome is a continued slowing trend to around 6.5% annually.

Caterpillar's big bet on China was grounded in its $7.6 billion acquisition of Bucyrus International, but as its fourth-quarter results showed, construction revenues tumbled in Asia 32% and were down on average 23% everywhere else in the world. Alcoa's earnings are due out April 8, and though 2013 was supposed to be the year when its recovery would take root, with China easing back on construction and aluminum prices only just beginning to recover, it's going to take some time for the global economy to gain traction. 

International wall of worry
Beyond the Dow components, mobile marketer Velti (NASDAQOTH: VELTF  ) was another one crushed by international intrigue, as its stock lost more than half its value after events in Greece and the Balkans caused it to divest assets there. It swung to a third-quarter loss, and analysts now worry it won't be able get costs under control, leading to widespread ratings downgrades.

The problem as Wall Street sees it is that Velti is forgoing significant business opportunities in the regions that were big contributors to sales and profits. Even with plans to focus instead on China and Western Europe, the marketer might run into the same problems as Alcoa and Caterpillar.

Last year, I suggested that a buyout was perhaps the best argument in favor of investing in Velti. Hedge-fund operator Discovery Group, however, thinks the market is mispricing the marketer and has taken a 5% stake in the shop. With fourth-quarter results due out soon, Velti will be inviting greater scrutiny to see if it can make the changes necessary.

The dilution solution
It might not have been the best of performances, but until last week, biotech Ziopharm Oncology (NASDAQ: ZIOP  ) was holding its own -- and then the bottom dropped out. The plunge and accompanying loss of two-thirds of its value happened because its soft tissue cancer treatment, palifosfamide, failed to achieve its goals in late-stage clinical trials. The drugmaker announced that it was cancelling further tests on the treatment, though it will convert an ongoing study for small-cell lung cancer into a midstage trial.

It's interesting to note, however, that the independent committee monitoring palifosfamide actually recommended continuing study on the trial's secondary endpoint for overall survival, but with little money in the bank, it can't afford go chasing such will-o'-the-wisps. According to its annual report filed just a few weeks ago, Ziopharm has just $73 million in the bank, which could be put to better use on a treatment that doesn't have such a high hurdle to climb.

Since Zopharm does have a few drugs it can pursue, it's probably going to need to tap the well of public equity or debt to finance its trials, which means investors are going to see their shares significantly diluted.

Because palifosfamide has been well tolerated in trials, this is a stock you may not want to completely remove from your watchlist, but as I noted last week, without any near-term catalysts to warrant investing in the company, it's a company better suited to day traders than long-term investors.

Ready for a resurrection
Materials industries are traditionally known for their high barriers to entry, and the aluminum industry is no exception. Controlling about 15% of global production in this highly consolidated industry, Alcoa is in prime position to take advantage of growth that some expect will lead to total industry revenue approaching $160 billion by 2017. Based on this prospect and several other company-specific factors, Alcoa is certainly worth a closer look. For a Foolish investment perspective on this global giant simply click here now to get started.

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2340454, ~/Articles/ArticleHandler.aspx, 9/27/2016 1:30:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,216.11 121.28 0.67%
S&P 500 2,159.18 13.08 0.61%
NASD 5,294.91 37.42 0.71%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 1:15 PM
AA $9.61 Down -0.07 -0.72%
Alcoa CAPS Rating: ***
CAT $82.69 Up +0.32 +0.39%
Caterpillar CAPS Rating: ***
VELTF $0.00 Up +0.00 +0.00%
Velti plc CAPS Rating: ****
ZIOP $5.42 Down -0.07 -1.28%
ZIOPHARM Oncology CAPS Rating: **